Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus

Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction and is associated with morbidity from embolic complications. Predicting which patients will develop death or persistent LVT despite anticoagulation may help clinicians identify high-risk patients. We developed a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thrombosis and thrombolysis 2021-08, Vol.52 (2), p.654-661
Hauptverfasser: Yeung, Wesley, Sia, Ching-Hui, Pollard, Tom, Leow, Aloysius Sheng-Ting, Tan, Benjamin Yong-Qiang, Kaur, Rajinderdeep, Yeo, Tiong-Cheng, Tay, Edgar Lik-Wui, Yeo, Leonard Leong-Litt, Chan, Mark Yan-Yee, Loh, Joshua Ping-Yun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 661
container_issue 2
container_start_page 654
container_title Journal of thrombosis and thrombolysis
container_volume 52
creator Yeung, Wesley
Sia, Ching-Hui
Pollard, Tom
Leow, Aloysius Sheng-Ting
Tan, Benjamin Yong-Qiang
Kaur, Rajinderdeep
Yeo, Tiong-Cheng
Tay, Edgar Lik-Wui
Yeo, Leonard Leong-Litt
Chan, Mark Yan-Yee
Loh, Joshua Ping-Yun
description Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction and is associated with morbidity from embolic complications. Predicting which patients will develop death or persistent LVT despite anticoagulation may help clinicians identify high-risk patients. We developed a random forest (RF) model that predicts death or persistent LVT and evaluated its performance. This was a single-center retrospective cohort study in an academic tertiary center. We included 244 patients with LVT in our study. Patients who did not receive anticoagulation (n = 8) or had unknown (n = 31) outcomes were excluded. The primary outcome was a composite outcome of death, recurrent LVT and persistent LVT. We selected a total of 31 predictors collected at the point of LVT diagnosis based on clinical relevance. We compared conventional regularized logistic regression with the RF algorithm. There were 156 patients who had resolution of LVT and 88 patients who experienced the composite outcome. The RF model achieved better performance and had an AUROC of 0.700 (95% CI 0.553–0.863) on a validation dataset. The most important predictors for the composite outcome were receiving a revascularization procedure, lower visual ejection fraction (EF), higher creatinine, global wall motion abnormality, higher prothrombin time, higher body mass index, higher activated partial thromboplastin time, older age, lower lymphocyte count and higher neutrophil count. The RF model accurately identified patients with post-AMI LVT who developed the composite outcome. Further studies are needed to validate its use in clinical practice.
doi_str_mv 10.1007/s11239-020-02368-1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2475093898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2586212698</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-cf9bec16fc1c0c022fd65377097ad11d1840848fdbb25a35d3eac403c140589b3</originalsourceid><addsrcrecordid>eNp9kU9rFTEUxYMo9rX6BVxIwI2Ljt4kk5nJUor_oKALBXchk2TalJlkvMlU3gfwexvfqxVcuAiXkN85J9xDyDMGrxhA_zozxoVqgEM9ohsa9oDsmOxF07f820OyA8VVIwXIE3Ka8w0AKAX8MTkRQgyqA7UjPz-jd8GWEK_okrCYOZT9OS3XmJZxyxS93RB9tJ6a6OjqMYdcDvcQ6WpK8LFk-iOUa7qmXBpjt-Lpsk_WoAtmrthksAakSGc_FXpbBRjsNhu8j3lCHk1mzv7p3TwjX9-9_XLxobn89P7jxZvLxrZMlcZOavSWdZNlFixwPrlOir4H1RvHmGNDC0M7TG4cuTRCOuGNbUFY1oIc1CjOyMuj74rp--Zz0UvI1s-ziT5tWfO2l6DqboaKvvgHvUkbxvo7zeXQcca7A8WPlMWUM_pJrxgWg3vNQP8uSR9L0rUkfShJsyp6fme9jYt395I_rVRAHIFcn-KVx7_Z_7H9BbTWoCg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2586212698</pqid></control><display><type>article</type><title>Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Yeung, Wesley ; Sia, Ching-Hui ; Pollard, Tom ; Leow, Aloysius Sheng-Ting ; Tan, Benjamin Yong-Qiang ; Kaur, Rajinderdeep ; Yeo, Tiong-Cheng ; Tay, Edgar Lik-Wui ; Yeo, Leonard Leong-Litt ; Chan, Mark Yan-Yee ; Loh, Joshua Ping-Yun</creator><creatorcontrib>Yeung, Wesley ; Sia, Ching-Hui ; Pollard, Tom ; Leow, Aloysius Sheng-Ting ; Tan, Benjamin Yong-Qiang ; Kaur, Rajinderdeep ; Yeo, Tiong-Cheng ; Tay, Edgar Lik-Wui ; Yeo, Leonard Leong-Litt ; Chan, Mark Yan-Yee ; Loh, Joshua Ping-Yun</creatorcontrib><description>Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction and is associated with morbidity from embolic complications. Predicting which patients will develop death or persistent LVT despite anticoagulation may help clinicians identify high-risk patients. We developed a random forest (RF) model that predicts death or persistent LVT and evaluated its performance. This was a single-center retrospective cohort study in an academic tertiary center. We included 244 patients with LVT in our study. Patients who did not receive anticoagulation (n = 8) or had unknown (n = 31) outcomes were excluded. The primary outcome was a composite outcome of death, recurrent LVT and persistent LVT. We selected a total of 31 predictors collected at the point of LVT diagnosis based on clinical relevance. We compared conventional regularized logistic regression with the RF algorithm. There were 156 patients who had resolution of LVT and 88 patients who experienced the composite outcome. The RF model achieved better performance and had an AUROC of 0.700 (95% CI 0.553–0.863) on a validation dataset. The most important predictors for the composite outcome were receiving a revascularization procedure, lower visual ejection fraction (EF), higher creatinine, global wall motion abnormality, higher prothrombin time, higher body mass index, higher activated partial thromboplastin time, older age, lower lymphocyte count and higher neutrophil count. The RF model accurately identified patients with post-AMI LVT who developed the composite outcome. Further studies are needed to validate its use in clinical practice.</description><identifier>ISSN: 0929-5305</identifier><identifier>EISSN: 1573-742X</identifier><identifier>DOI: 10.1007/s11239-020-02368-1</identifier><identifier>PMID: 33389609</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aged ; Anticoagulants - therapeutic use ; Blood clots ; Body mass index ; Cardiology ; Cell number ; Creatinine ; Death ; Heart ; Heart attacks ; Hematology ; Humans ; Leukocytes (neutrophilic) ; Lymphocytes ; Medicine ; Medicine &amp; Public Health ; Morbidity ; Myocardial infarction ; Myocardial Infarction - complications ; Patients ; Prothrombin ; Retrospective Studies ; Risk groups ; Thromboplastin ; Thrombosis ; Ventricle ; Ventricular Function, Left</subject><ispartof>Journal of thrombosis and thrombolysis, 2021-08, Vol.52 (2), p.654-661</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-cf9bec16fc1c0c022fd65377097ad11d1840848fdbb25a35d3eac403c140589b3</citedby><cites>FETCH-LOGICAL-c419t-cf9bec16fc1c0c022fd65377097ad11d1840848fdbb25a35d3eac403c140589b3</cites><orcidid>0000-0002-3224-8954</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11239-020-02368-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11239-020-02368-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33389609$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yeung, Wesley</creatorcontrib><creatorcontrib>Sia, Ching-Hui</creatorcontrib><creatorcontrib>Pollard, Tom</creatorcontrib><creatorcontrib>Leow, Aloysius Sheng-Ting</creatorcontrib><creatorcontrib>Tan, Benjamin Yong-Qiang</creatorcontrib><creatorcontrib>Kaur, Rajinderdeep</creatorcontrib><creatorcontrib>Yeo, Tiong-Cheng</creatorcontrib><creatorcontrib>Tay, Edgar Lik-Wui</creatorcontrib><creatorcontrib>Yeo, Leonard Leong-Litt</creatorcontrib><creatorcontrib>Chan, Mark Yan-Yee</creatorcontrib><creatorcontrib>Loh, Joshua Ping-Yun</creatorcontrib><title>Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus</title><title>Journal of thrombosis and thrombolysis</title><addtitle>J Thromb Thrombolysis</addtitle><addtitle>J Thromb Thrombolysis</addtitle><description>Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction and is associated with morbidity from embolic complications. Predicting which patients will develop death or persistent LVT despite anticoagulation may help clinicians identify high-risk patients. We developed a random forest (RF) model that predicts death or persistent LVT and evaluated its performance. This was a single-center retrospective cohort study in an academic tertiary center. We included 244 patients with LVT in our study. Patients who did not receive anticoagulation (n = 8) or had unknown (n = 31) outcomes were excluded. The primary outcome was a composite outcome of death, recurrent LVT and persistent LVT. We selected a total of 31 predictors collected at the point of LVT diagnosis based on clinical relevance. We compared conventional regularized logistic regression with the RF algorithm. There were 156 patients who had resolution of LVT and 88 patients who experienced the composite outcome. The RF model achieved better performance and had an AUROC of 0.700 (95% CI 0.553–0.863) on a validation dataset. The most important predictors for the composite outcome were receiving a revascularization procedure, lower visual ejection fraction (EF), higher creatinine, global wall motion abnormality, higher prothrombin time, higher body mass index, higher activated partial thromboplastin time, older age, lower lymphocyte count and higher neutrophil count. The RF model accurately identified patients with post-AMI LVT who developed the composite outcome. Further studies are needed to validate its use in clinical practice.</description><subject>Aged</subject><subject>Anticoagulants - therapeutic use</subject><subject>Blood clots</subject><subject>Body mass index</subject><subject>Cardiology</subject><subject>Cell number</subject><subject>Creatinine</subject><subject>Death</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphocytes</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Morbidity</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - complications</subject><subject>Patients</subject><subject>Prothrombin</subject><subject>Retrospective Studies</subject><subject>Risk groups</subject><subject>Thromboplastin</subject><subject>Thrombosis</subject><subject>Ventricle</subject><subject>Ventricular Function, Left</subject><issn>0929-5305</issn><issn>1573-742X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU9rFTEUxYMo9rX6BVxIwI2Ljt4kk5nJUor_oKALBXchk2TalJlkvMlU3gfwexvfqxVcuAiXkN85J9xDyDMGrxhA_zozxoVqgEM9ohsa9oDsmOxF07f820OyA8VVIwXIE3Ka8w0AKAX8MTkRQgyqA7UjPz-jd8GWEK_okrCYOZT9OS3XmJZxyxS93RB9tJ6a6OjqMYdcDvcQ6WpK8LFk-iOUa7qmXBpjt-Lpsk_WoAtmrthksAakSGc_FXpbBRjsNhu8j3lCHk1mzv7p3TwjX9-9_XLxobn89P7jxZvLxrZMlcZOavSWdZNlFixwPrlOir4H1RvHmGNDC0M7TG4cuTRCOuGNbUFY1oIc1CjOyMuj74rp--Zz0UvI1s-ziT5tWfO2l6DqboaKvvgHvUkbxvo7zeXQcca7A8WPlMWUM_pJrxgWg3vNQP8uSR9L0rUkfShJsyp6fme9jYt395I_rVRAHIFcn-KVx7_Z_7H9BbTWoCg</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Yeung, Wesley</creator><creator>Sia, Ching-Hui</creator><creator>Pollard, Tom</creator><creator>Leow, Aloysius Sheng-Ting</creator><creator>Tan, Benjamin Yong-Qiang</creator><creator>Kaur, Rajinderdeep</creator><creator>Yeo, Tiong-Cheng</creator><creator>Tay, Edgar Lik-Wui</creator><creator>Yeo, Leonard Leong-Litt</creator><creator>Chan, Mark Yan-Yee</creator><creator>Loh, Joshua Ping-Yun</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3224-8954</orcidid></search><sort><creationdate>20210801</creationdate><title>Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus</title><author>Yeung, Wesley ; Sia, Ching-Hui ; Pollard, Tom ; Leow, Aloysius Sheng-Ting ; Tan, Benjamin Yong-Qiang ; Kaur, Rajinderdeep ; Yeo, Tiong-Cheng ; Tay, Edgar Lik-Wui ; Yeo, Leonard Leong-Litt ; Chan, Mark Yan-Yee ; Loh, Joshua Ping-Yun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-cf9bec16fc1c0c022fd65377097ad11d1840848fdbb25a35d3eac403c140589b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Anticoagulants - therapeutic use</topic><topic>Blood clots</topic><topic>Body mass index</topic><topic>Cardiology</topic><topic>Cell number</topic><topic>Creatinine</topic><topic>Death</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphocytes</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Morbidity</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - complications</topic><topic>Patients</topic><topic>Prothrombin</topic><topic>Retrospective Studies</topic><topic>Risk groups</topic><topic>Thromboplastin</topic><topic>Thrombosis</topic><topic>Ventricle</topic><topic>Ventricular Function, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yeung, Wesley</creatorcontrib><creatorcontrib>Sia, Ching-Hui</creatorcontrib><creatorcontrib>Pollard, Tom</creatorcontrib><creatorcontrib>Leow, Aloysius Sheng-Ting</creatorcontrib><creatorcontrib>Tan, Benjamin Yong-Qiang</creatorcontrib><creatorcontrib>Kaur, Rajinderdeep</creatorcontrib><creatorcontrib>Yeo, Tiong-Cheng</creatorcontrib><creatorcontrib>Tay, Edgar Lik-Wui</creatorcontrib><creatorcontrib>Yeo, Leonard Leong-Litt</creatorcontrib><creatorcontrib>Chan, Mark Yan-Yee</creatorcontrib><creatorcontrib>Loh, Joshua Ping-Yun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and thrombolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yeung, Wesley</au><au>Sia, Ching-Hui</au><au>Pollard, Tom</au><au>Leow, Aloysius Sheng-Ting</au><au>Tan, Benjamin Yong-Qiang</au><au>Kaur, Rajinderdeep</au><au>Yeo, Tiong-Cheng</au><au>Tay, Edgar Lik-Wui</au><au>Yeo, Leonard Leong-Litt</au><au>Chan, Mark Yan-Yee</au><au>Loh, Joshua Ping-Yun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus</atitle><jtitle>Journal of thrombosis and thrombolysis</jtitle><stitle>J Thromb Thrombolysis</stitle><addtitle>J Thromb Thrombolysis</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>52</volume><issue>2</issue><spage>654</spage><epage>661</epage><pages>654-661</pages><issn>0929-5305</issn><eissn>1573-742X</eissn><abstract>Left ventricular thrombus (LVT) is a common complication of acute myocardial infarction and is associated with morbidity from embolic complications. Predicting which patients will develop death or persistent LVT despite anticoagulation may help clinicians identify high-risk patients. We developed a random forest (RF) model that predicts death or persistent LVT and evaluated its performance. This was a single-center retrospective cohort study in an academic tertiary center. We included 244 patients with LVT in our study. Patients who did not receive anticoagulation (n = 8) or had unknown (n = 31) outcomes were excluded. The primary outcome was a composite outcome of death, recurrent LVT and persistent LVT. We selected a total of 31 predictors collected at the point of LVT diagnosis based on clinical relevance. We compared conventional regularized logistic regression with the RF algorithm. There were 156 patients who had resolution of LVT and 88 patients who experienced the composite outcome. The RF model achieved better performance and had an AUROC of 0.700 (95% CI 0.553–0.863) on a validation dataset. The most important predictors for the composite outcome were receiving a revascularization procedure, lower visual ejection fraction (EF), higher creatinine, global wall motion abnormality, higher prothrombin time, higher body mass index, higher activated partial thromboplastin time, older age, lower lymphocyte count and higher neutrophil count. The RF model accurately identified patients with post-AMI LVT who developed the composite outcome. Further studies are needed to validate its use in clinical practice.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33389609</pmid><doi>10.1007/s11239-020-02368-1</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3224-8954</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0929-5305
ispartof Journal of thrombosis and thrombolysis, 2021-08, Vol.52 (2), p.654-661
issn 0929-5305
1573-742X
language eng
recordid cdi_proquest_miscellaneous_2475093898
source MEDLINE; SpringerLink (Online service)
subjects Aged
Anticoagulants - therapeutic use
Blood clots
Body mass index
Cardiology
Cell number
Creatinine
Death
Heart
Heart attacks
Hematology
Humans
Leukocytes (neutrophilic)
Lymphocytes
Medicine
Medicine & Public Health
Morbidity
Myocardial infarction
Myocardial Infarction - complications
Patients
Prothrombin
Retrospective Studies
Risk groups
Thromboplastin
Thrombosis
Ventricle
Ventricular Function, Left
title Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A57%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicting%20mortality,%20thrombus%20recurrence%20and%20persistence%20in%20patients%20with%20post-acute%20myocardial%20infarction%20left%20ventricular%20thrombus&rft.jtitle=Journal%20of%20thrombosis%20and%20thrombolysis&rft.au=Yeung,%20Wesley&rft.date=2021-08-01&rft.volume=52&rft.issue=2&rft.spage=654&rft.epage=661&rft.pages=654-661&rft.issn=0929-5305&rft.eissn=1573-742X&rft_id=info:doi/10.1007/s11239-020-02368-1&rft_dat=%3Cproquest_cross%3E2586212698%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2586212698&rft_id=info:pmid/33389609&rfr_iscdi=true